Advantage of delayed whole-body FDG-PET imaging for tumour detection

European Journal of Nuclear Medicine

Volumn 28, Issue 6, 2001, Pages 696-703

  Kubota, Kazuo ^a   Itoh, Masatoshi ^a   Ozaki, Kaoru ^a   Ono, Shuichi ^a   Tashiro, Manabu ^a   Yamaguchi, Keiichiro ^a   Akaizawa, Takashi ^a   Yamada, Kenji ^b   Fukuda, Hiroshi ^a  

^a TOHOKU UNIVERSITY   (Japan)

^b NONE

Author keywords

Delayed imaging; Fluorine 18 fluorodeoxyglucose; Lung cancer; Positron emission tomography; Tumour detection

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ARTICLE; BREAST CANCER; CARCINOID; CLINICAL ARTICLE; COLON CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; GLUCOSE TRANSPORT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG CANCER; LYMPH NODE METASTASIS; LYMPHOMA; MEDIASTINUM LYMPH NODE; MESOTHELIOMA; MULTIPLE MYELOMA; POSITRON EMISSION TOMOGRAPHY; SARCOIDOSIS; TUMOR DIAGNOSIS;

FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; LYMPH NODES; MESOTHELIOMA; NEOPLASMS; RADIOPHARMACEUTICALS; SARCOIDOSIS; TIME FACTORS; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED; WHOLE-BODY COUNTING;

EID: 0035019192     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590100537     Document Type: Article

References (25)

1. 18F]-FDG in oncology: a clinical update. Nucl Med Biol 1996; 23:717-735.
2. Kubota K, Matsuzawa T, Fujiwara T, et al. Differential diagnosis of lung tumor with positron emission tomography: a prospective study. J Nucl Med 1990; 31:1927-1933.
3. Coleman RE. PET in lung cancer. J Nucl Med 1999; 40:814-820.
4. Moog F, Bangerter M, Diederichs CG, et al. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose(FDG) PET in nodal staging. Radiology 1997; 203:795-800.
5. Moog F, Bangerter M, Diederichs CG, et al. Extranodal malignant lymphoma: detection with FDG-PET versus CT. Radiology 1998; 206:475-481.
6. Wahl RL, Cody RL, Hutchins GD, Mudgett EE. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2- deoxy-D-glucose. Radiology 1991; 179:765-770.
7. Adler LP, Faulhaber PF, Schnur KC, Al-Kasi NL, Shenk RR. Axillary lymph node metastasis: screening with [F-18]2-deoxy- 2-fluoro-D-glucose (FDG) PET. Radiology 1997; 203:323-327.
8. 11C]deoxy- glucose. J Cereb Blood Flow Metab 1985; 5:179-192.
9. Nolop KB, Rhodes CG, Brudin LH, et al. Glucose utilization in vivo by human pulmonary neoplasms. Cancer 1987; 60:2682-2689.
10. Lindholm P, Minn H, Leskinen S, Bergman J, Ruotsalainen U, Joensuu H. Influence of the blood glucose concentration on FDG uptake in cancer - a PET study. J Nucl Med 1993; 34:1-6.
11. Imran MB, Kubota K, Yamada S, et al. Lesion-to-background ratio in nonattenuation corrected whole-body FDG PET images. J Nucl Med 1998; 39:1219-1223.
12. Kubota R, Kubota K, Yamada S, Tada M, Ido T, Tamahashi N. Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake. J Nucl Med 1994; 35:104-112.
13. Lowe VJ, Delong DM, Hoffman JM, Coleman RE. Optimum scanning protocol for FDG-PET evaluation of pulmonary malignancy. J Nucl Med 1995; 36:883-887.
14. Hamberg LM, Hunter GJ, Alpert NM, Choi NC, Babich JW, Fischman AJ. The dose uptake ratio as index of glucose metabolism: useful parameter or oversimplification? J Nucl Med 1994; 35:1308-1312.
15. Hoegerle S, Juengling F, Otte A, Altehoefer C, Moser EA, Nitzsche EU. Combined FDG and [F-18]fluoride whole-body PET: a feasible two-in-one approach to cancer imaging? Radiology 1998; 209:253-258.
16. Hustinx R, Smith RJ, Benard F, et al. Dual time point fluorine- 18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med 1999; 26:1345-1348.
17. Boemer AR, Weckesser M, Herzog H, et al. Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer. Eur J Nucl Med 1999;26:226-230.
18. 18F]FDG using tetrabutylammonium bicarbonate. Appl Radiat Isot 1995; 46:887-891.
19. Fujiwara T, Watanuki S, Yamamoto S, et al. Performance evaluation of a large axial field-of-view PET scanner: SET- 2400 W. Ann Nucl Med 1997; 11:307-313.
20. Kubota K, Matsuzawa T, Ito M, et al. Lung tumor imaging by positron emission tomography using C-11 L-methionine. J Nucl Med 1985; 26:37-42.
21. Nakamoto Y, Higashi T, Sakahara H, Tamaki N, Imamura M, Konishi J. Delayed FDG-PET scan for the differentiation between malignant and benign lesions. J Nucl Med 1999; 40:247p.
22. Waki A, Fujibayashi Y, Yokoyama A. Recent advances in the analyses of the characteristics of tumors on FDG uptake. Nucl Med Biol 1998; 25:589-592.
23. Waki A, Kato H, Yano R, et al. The importance of glucose transport activity as the rate-limiting step of 2-deoxyglucose uptake in tumor cells in vitro. Nucl Med Biol 1998; 25: 593-597.
24. Brown RS, Leung JY, Fisher SJ, et al. Intratumoral distribution of tritiated-FDG in breast carcinoma: correlation between Glut-1 expression and FDG uptake. J Nucl Med 1996; 37:1042-1047.
25. Brown RS, Leung JY, Kison PV, Zasadny KR, Flint A, Wahl RL. Glucose transporters and FDG uptake in untreated primary human non-small cell lung cancer. J Nucl Med 1999; 40:556-565.